AKT1 and renal cell adenocarcinoma: We found that combining the two drugs had a strong additive effect in inhibiting the proliferation of RCC cells and increasing apoptosis; the drug combination blocked the activity of the Pro‐survival kinase Akt and inhibited tumor progression.